Now indicated for Correction of Age Related Volume Loss in the Cheek Area.
Galderma, a global healthcare company focused on skin health, announced today that it has received US Food and Drug Administration (FDA) approval to market Restylane® Lyft for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. Restylane® Lyft, formerly marketed as Perlane-L®, is an injectable gel used to increase volume and smooth wrinkles in the face. With this new indication, Restylane® Lyft is the first and only FDA approved filler indicated to provide fullness to the midface area and to correct and smooth the nasolabial folds.
‘Consumers are looking for safe, high quality products that can deliver natural-looking results. This new indication demonstrates the versatility of Restylane® Lyft and its efficacy in addressing smile lines and restoring structure to the cheeks and midface area,’ said Kelly Huang, PhD, Vice President and General Manager of Galderma’s Aesthetic and Corrective Business Unit in the US. ‘With more than 15 years of proven safety data and approximately 6 million treatments worldwide, Restylane® Lyft is a trusted, safe and effective product and we are proud to be able to expand our offering to healthcare providers and consumers in the US.’
This FDA approval marks the fifth major indication in the US for the Restylane® family of products. Restylane® Lyft joins Restylane®, indicated to correct and smooth smile lines as well as to augment the lips, and Restylane® Silk, the first and only treatment that is approved for lip enhancement and the treatment of wrinkles and lines around the mouth. These brands combined represent the broadest range of dermal fillers with the most FDA approved indications commercially available for healthcare professionals and patients.
In a clinical trial involving 200 patients, investigators observed that 88.7% of patients treated with Restylane® Lyft showed an improvement in fullness in the right and left midface areas (combined) at 2 months, and more than half maintained improvement for 12 months. Additionally, 95% of patients reported improvement with the appearance of their midface at 2 months and 73% of patients reported improvement at 12 months. The most common adverse events observed in the trial included: tenderness, redness, bruising, swelling, and itching. These events decreased in severity over time and most were resolved within 2 weeks.
The brand name is changing from Perlane-L® to Restylane® Lyft to help health care providers and consumers understand where the brand fits among the other Galderma products that are based on the core Restylane® technology.